Treatment-resistant mood disorders;Transtornos de humor refratários a tratamento

Revista Brasileira de Psiquiatria

Volumn 29, Issue SUPPL. 2, 2007, Pages

  Machado Vieira, Rodrigo ^a,c   Soares, Jair C ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Bldg 35 ^*  (United States)

Author keywords

Antidepressive agents; Bipolar disorder; Depressive disorder, major; Mood disorders; Refractory period, psychological

Indexed keywords

ANTIDEPRESSANT AGENT; GLUCOCORTICOID; MOOD STABILIZER;

ARTICLE; DEPRESSION; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG RESISTANCE; HEREDITY; HUMAN; MONOAMINERGIC SYSTEM; MOOD DISORDER; MORBIDITY; NERVE CELL PLASTICITY; PREVALENCE; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE;

EID: 37849037050     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462006005000058     Document Type: Article

References (50)

1. Rush AJ. Toward an understanding of bipolar disorder and its origin. J Clin Psychiatry. 2003;64(Suppl 6):18-22; discussion 28.
2. Katz MM, Koslow SH, Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety. 1996-1997;4(6):257-67.
3. Post RM. Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database. Expert Opin Pharmacother. 2005;6(4): 531-46.
4. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-7.
5. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry. 1994;55(Suppl):20-6.
6. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med. 1998;28(3):731-5.
7. Lewis L, Hoofnagle L. Treatment-resistant depression: the patient perspective. Biol Psychiatry. 2003;53(8):635-9.
8. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152(11):1635-40.
9. Parker G, Wilhelm K, Mitchell P, Gladstone G . Predictors of 1-year outcome in depression. Aust N Z J Psychiatry. 2000;34(1):56-64.
10. Fava M, Vuolo RD, Wright EC, Nierenberg AA, Alpert JE, Rosenbaum JF . Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000;94(1):9-18.
11. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ: STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
12. Kupfer DJ, Charney DS. Difficult-to-treat depression. Biol Psychiatry. 2003;53(8):633-4.
13. Machado-Vieira R, Zarate CA, Manji HK. Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades. Current Psychosis Ther Rep. 2006;4(4):181-90.
14. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88.
15. Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, Cadevall J, Garcia-Castrillon J, Lusilla P, Arrufat F. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol. 2002;22(4):431-5.
16. Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Power KB, Sacher JA.. Integrated family and individual therapy for bipolar disorder: results of a treatment development study. J Clin Psychiatry. 2003;64(2):182-91.
17. Singh JB, Zarate CA Jr. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord. 2006;8(6):696-709.
18. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord. 1990;18(4):259-66.
19. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry. 1991;159:123-9.
20. Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, Leverich G, Frye M . Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 1996;11:153-80.
21. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61(2):142-4.
22. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48(8):740-54.
23. Manji HK, Lenox RH. The nature of bipolar disorder. J Clin Psychiatry. 2000;61(Supp 13):42-57.
24. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001;35(2):5-49.
25. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430-2.
26. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50(4):260-5.
27. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005;57(9):1068-72.
28. Chen G, Manji HK. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry. 2006 ;19(3):313-23.
29. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff KA, Gray N, Zarate CA Jr, Charney DS. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53(8):707-42.
30. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005;30(7):1223-37.
31. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
32. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-27.
33. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99(1):45-53.
34. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52(5):386-92.
35. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61(12):1235-44.
36. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther. 2004;311(2):427-40.
37. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann N Y Acad Sci. 1995;774:337-9.
38. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001;11(2):240-9.
39. Hough C, Lu SJ, Davis CL, Chuang DM, Post RM. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry. 1999;46(2):247-55.
40. Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, Manji HK. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003;1003:273-91.
41. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20(1):8-21.
42. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska E. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002 ;440(1):27-35.
43. Du J, Machado-Vieira R, Maeng S, Martinowich K, Manji HK, Zarate CA. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov Today. 2007;12(3-4):519-26.
44. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161(1):171-4.
45. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
46. Silvestre JS, Nadal R, Pallares M, Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety. 1997;5(1):29-33.
47. Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, Theodore WH. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res. 1996;23(2):129-37.
48. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol Rep. 2005;57(6):713-8.
49. Ogren SO, Kuteeva E, Hokfelt T, Kehr J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs. 2006;20(8):633-54.
50. Fleck MP, Horwath E. Pharmacologic management of difficult-to-treat depression in clinical practice. Psychiatr Serv. 2005;56(8):1005-11.